Interní Med. 2016; 18(2): 78-82 | DOI: 10.36290/int.2016.019

New peroral antidiabetic drugs and heart failure

MUDr.Jana Jiráčková, doc.MUDr.Alena Šmahelová, Ph.D.

¹ III. interní gerontometabolická klinika, Fakultní nemocnice Hradec Králové

² Ústav klinické biochemie a diagnostiky, Fakultní nemocnice Hradec Králové

³ Univerzita Karlova v Praze, Lékařská fakulta Hradec Králové

Important risk factors of chronic heart failure (CHF) i diabetics represent ischaemic heart disease and arterial hypertension as well

as diabetic cardiomyopathy (specific heart tissue impairment of diabetes mellitus). Optimal diabetic compensation is essential

for prevention and treatment of CHF. A wide range of antidiabetic drugs can lower effectively blood glucose as well as improve

cardiovascular parameters. Metformin – traditional antidiabetic drug is a very effective insulin sensitizer with positive cardiovascular

effect; metformin can be used in patients with compensated CHF. Gliptins, modern peroral antidiabetic drugs, are used

in patients with cardiovascular complications however results of recent cardiovascular studies (SAVOR, TECOS, EXAMINE) were

a bit confusing. Gliflozines on the other hand have become very promising for patients with CHF, based on results of EMPA-REG

presenting statistically significant reduction in cardiovascular mortality and complications of chronic heart failure.

Keywords: chronical heart failure, gliflozins, gliptins

Published: May 1, 2016  Show citation